Patient readmissions · adults
Medication reconciliation: pharmacist showed no clear difference in readmission at 1 month ( compared with other professionals (moderate certainty).
1 finding from 1 review
Length of stay · adults
1 finding from 1 review
Quality of life (VAS 0‐10; EQ‐5D‐3L) ( · adults
1 finding from 1 review
Discrepancy resolution ( · adults
Medication reconciliation: pharmacist may leads to higher discrepancy resolution ( compared with other professionals (low certainty).
1 finding from 1 review
ADEs ( · adults
Medication reconciliation: pharmacist showed no clear difference in ADEs ( compared with other professionals (low certainty).
1 finding from 1 review
Mortality during hospitalisation ( · adults
Medication reconciliation: pharmacist showed no clear difference in mortality during hospitalisation ( compared with other professionals (moderate certainty).
1 finding from 1 review
PADEs · all patients (aged > 18 years) at a transition of care
It is very uncertain whether medication reconciliation interventions changes PADEs compared with standard care (very low certainty).
1 finding from 1 review
ADEs ( · all patients (aged > 18 years) at a transition of care
Medication reconciliation interventions showed no clear difference in ADEs compared with standard care (low certainty).
1 finding from 1 review
Unplanned rehospitalisation · all patients (aged > 18 years) at a transition of care
Medication reconciliation interventions showed no clear difference in unplanned rehospitalisation compared with standard care (moderate certainty).
1 finding from 1 review
Hospital usage (composite measure of ED, rehospitalisation) · all patients (aged > 18 years) at a transition of care
It is very uncertain whether medication reconciliation interventions changes hospital usage (composite measure of ED, rehospitalisation) compared with standard care (very low certainty).
1 finding from 1 review
Retention [ · patients with opioid dependence
Supervised dosing with a long‐acting medication showed no clear difference in retention ‐ retention at the end of treatment (number of participants) compared with unsupervised consumption (low certainty).
2 findings from 1 review
Adverse serious events (any) (number of participants) · patients with opioid dependence
It is very uncertain whether supervised dosing with a long‐acting medication changes adverse serious events (any) (number of participants) compared with unsupervised consumption (very low certainty).
1 finding from 1 review
Abstinence from unsanctioned opioid use (number of participants with urine drug screen or self‐report use) · patients with opioid dependence
1 finding from 1 review
Diversion (number of participants) · patients with opioid dependence
1 finding from 1 review
Days of unsanctioned opioid use · patients with opioid dependence
1 finding from 1 review
Mortality ‐ (number of participants) · patients with opioid dependence
1 finding from 1 review
Acute rejection · solid organ transplant recipients with CMV viraemia
1 finding from 1 review
Leucopenia · solid organ transplant recipients with CMV viraemia
1 finding from 1 review
D+/R‐ serostatus: symptomatic CMV · solid organ transplant recipients with CMV viraemia
1 finding from 1 review
D+ or D‐/R+ serostatus: symptomatic CMV · solid organ transplant recipients with CMV viraemia
1 finding from 1 review